價(jià)格 | ¥17500 | ¥10600 | ¥13800 |
包裝 | 100mg | 25mg | 50mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-02 |
中文名稱:化合物 hMAO-B-IN-2 | 英文名稱:hMAO-B-IN-2 |
CAS:2454459-87-9 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Shipping with blue ice. |
產(chǎn)品類別: 抑制劑 | |
貨號(hào): T60678 |
Name | hMAO-B-IN-2 |
Description | hMAO-B-IN-2 (compound 6j) is an orally active, potent, selective and BBB penetrated and competitive reversible inhibitor of hMAO-B (IC 50 = 4 nM) that can be used for the research of alzheimer’s disease. hMAO-B-IN-2 exhibits good neuroprotective effects and low toxicity in SH-SY5Y cell [1]. |
In vitro | hMAO-B-IN-2 (compound 6j) (0-100 μM, 15 min) exhibits potent inhibitory activity, with IC 50 values of 4 nM (hMAO-B) and 6.04 nM (hMAO-A), respectively [1]. hMAO-B-IN-2 (30 min) is a reversible MAO-B inhibitor, the activity of MAO-B enzyme was restored to about 82% and 45% after compound 6j dilution to 0.1 × IC 50 and 1 × 50, respectively [1]. hMAO-B-IN-2 (25 μM, 48 h) exhibits remarkable inhibitory activities against MAO-B, had good inhibition property of Aβ self-induce aggregation (40.78 ± 6.27%) [1]. hMAO-B-IN-2 (0-100 μM, 24 h) shows non-toxic at the concentrations of 25 μM [1]. hMAO-B-IN-2 (0-25 μM, 24 h) has neuroprotective capability against neurodegeneration disease, and increases cell survival rates in a dose-dependent manner [1]. Cell Cytotoxicity Assay Cell Line: SH-SY5Y neuroblastoma cell [1] Concentration: 0, 6.25, 12.5, 25, 50, 100 μM Incubation Time: 24 h Result: Showed non-toxic at the concentrations of 25 μM. |
In vivo | hMAO-B-IN-2 (compound 6j) (Sprague-Dawley rats; 3 mg/kg, IV; 10 mg/kg, PO; once) has acceptable pharmacokinetic properties [1]. Pharmacokinetic Parameters of hMAO-B-IN-2 in male Sprague-Dawley rats [1]. Parameters IV (3 mg/kg) PO (10 mg/kg) T 1/2 (h) 1.02 ± 0.17 1.33 ± 0.16 T max (h) 0.3 C max (μg/L) 639.29 ± 89.06 142.17 ± 72.21 AUC 0-inf (μg/L h) 247.74 ± 11.48 268.49 ± 69.72 CL (L/h/kg) 3.33 ± 0.15 F (%) 36.10% Animal Model: Sprague-Dawley rats (male, 220±20 g) [1] Dosage: 3 mg/kg (IV), 10 mg/kg (PO) Administration: IV, PO (Pharmacokinetic Analysis) Result: Had acceptable pharmacokinetic properties, and showed a high maximal concentration, appropriate half-life, and good oral bioavailability. |
Storage | Shipping with blue ice. |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 589.8595萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP1年
|
陜西西化化學(xué)工業(yè)有限公司
|
2024-12-31 | |
¥1000 |
VIP1年
|
康邁迪森(北京)醫(yī)藥科技有限公司
|
2024-12-12 | |
詢價(jià) |
VIP12年
|
深圳振強(qiáng)生物技術(shù)有限公司
|
2025-02-08 |